In this proposal, we will determine how key innate immune response pathways to viral infection are altered in human cancer cells, particularly by comparing primary innate immune sentinel myeloid cells to their transformed counterparts. We will investigate the mechanistic roles of virus sensing pathways and their linkage to downstream innate immune responses via inflammasomes and NF-?B signaling in determining the tropism and sensing of myxoma virus (MYXV), a rabbit specific poxvirus that also exhibits the capacity to infect a wide spectrum of human cancer cells. We will investigate MYXV sensing and infection of human myeloid cells, especially monocyte-derived macrophages and dendritic cells. We will examine the molecular mechanisms used by MYXV-encoded pyrin domain (PYD)-containing host range protein M013 to co-regulate two distinct innate immune pathways of human myeloid cells, particularly as mediated by inflammasomes and by the NF-?B -mediated inflammatory signaling responses. We have reported that M013 binds the cellular adaptor protein ASC-1 (apoptosis-associated speck-like protein containing a CARD) of various inflammasome complexes and NF-?B1/p105 of NF-?B signaling pathway. Investigation of this unique co-regulation will have potential clinical utility for developing drugs having the capacity o target multiple inflammatory signaling pathways. Finally, we will take advantage of our knowledge of regulation of the inflammasome and NF-?B pathways to study the mechanism(s) of oncolysis by MYXV using myeloid leukemia models. Using knock-out mice for key innate immune pathways and MYXV constructed mutated at the M013 locus, we will study the role of these pathways in MYXV virotherapy for myeloid cancer. The three overlapping areas to be investigated in this proposal are:
Aim 1. Study the alteration of sensing pathways due to transformation of human myeloid cells and its impact on MYXV tropism: We will determine the role of RLR and TLR signaling in inducing type I IFN and pro-inflammatory cytokines in human myeloid cells that are permissive for MYXV (eg transformed myeloid cell lines like THP-1) or nonpermissive (eg primary human monocytes/macrophages);determine the role of NLRP3 inflammasome components and NF-?B1 in the synthesis of precursor IL-1? and IL-18 and release of these mature cytokines in response to MYXV infection;study the co-ordinating upstream role of virus-induced MAPK, in particular the role of MEK1/2-ERK1/2 kinases, in co-inducing both the type I IFN and pro-inflammatory cytokine signaling pathways in response to MYXV infection;and identify specifically which cellular sensor/transducer components become dysfunctional in transformed human myeloid cells.
Aim 2. Create engineered variants of the PYD-containing protein M013 that differentially regulate the inflammasome and NF-?B signaling pathways and test these M013 constructs in an in vivo caspase 1- dependent rat transplant vascular disease model: We will generate M013 mutants that selectively inhibit either the inflammasome or NF-?B pathways by interaction with only ASC-1 or NF-?B1 and exploit these mutants to construct recombinant MYXVs to test their effects in the myeloid cells described above;we will also test M013 variants engineered to allow intracellular penetration in a rat allograft transplant vascular disease (TVD) model that has been shown to be regulated by inflammasome-mediated activation of caspase 1.
Aim 3. Elucidate the roles of host inflammasomes and NF-?B signaling in MYXV-induced oncolytic clearance of myeloid cancer in situ: We will compare the roles of key inflammasome and NF-?B components (ie ASC-1, caspase-1, NLRP3 and NF-?B1) in MYXV-induced anti-tumor responses and clearance of human (eg THP-1) or murine (eg RAW426.7) myeloid leukemias in NSG immunocompromised mice and in C57BL/6-based immunocompetent mouse models, respectively;study the role of M013 variants in selective knockout mice using the M013KO vs wild-type MYXV, and the M013 variant-expressing viruses that selectively inhibit only the inflammasome or NF-?B pathways.

Public Health Relevance

This project addresses several important central issues that have broad application in the areas of virus tropism and viral oncolysis of cancer cells. Those include: how transformation of primary innate immune sentinel cells to their transformed counterparts alters the sensing and innate responses to viruses, how and why innate immune signaling pathways are co-regulated by viruses, and why innate immune signaling pathways are important for oncolytic virotherapy. The proposed studies will demonstrate the role of key immune pathways in transformed vs primary human myeloid cells, how co-regulation of innate signaling pathways can benefit the virus and provide new therapeutic strategies to treat various inflammatory diseases. The model virus proposed here is Myxoma virus (MYXV), which infects only rabbits in nature, and has significant potential for the treatment of human cancers like myeloid leukemia and multiple myeloma. The knowledge that will be gained from this project will have broader implications in the treatment of human cancers using MYXV and can be applicable for other oncolytic viruses as well.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI100987-01A1
Application #
8501735
Study Section
Special Emphasis Panel (ZRG1-IDM-S (02))
Program Officer
Palker, Thomas J
Project Start
2013-01-01
Project End
2017-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
1
Fiscal Year
2013
Total Cost
$372,500
Indirect Cost
$122,500
Name
University of Florida
Department
Genetics
Type
Schools of Medicine
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Ambadapadi, Sriram; Munuswamy-Ramanujam, Ganesh; Zheng, Donghang et al. (2016) Reactive Center Loop (RCL) Peptides Derived from Serpins Display Independent Coagulation and Immune Modulating Activities. J Biol Chem 291:2874-87
Liu, Jia; McFadden, Grant (2015) SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses. J Virol 89:1925-31
Ildefonso, Cristhian J; Jaime, Henrique; Rahman, Masmudur M et al. (2015) Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation. Hum Gene Ther 26:59-68
Boutard, Bérengère; Vankerckhove, Sophie; Markine-Goriaynoff, Nicolas et al. (2015) The α2,3-sialyltransferase encoded by myxoma virus is a virulence factor that contributes to immunosuppression. PLoS One 10:e0118806
Villa, Nancy Y; Wasserfall, Clive H; Meacham, Amy M et al. (2015) Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood 125:3778-88
McKenzie, Brienne A; Zemp, Franz J; Pisklakova, Alexandra et al. (2015) In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro Oncol 17:1086-94
Tosic, Vesna; Thomas, Diana L; Kranz, David M et al. (2014) Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity. PLoS One 9:e109801
Chan, Winnie M; McFadden, Grant (2014) Oncolytic Poxviruses. Annu Rev Virol 1:119-141
Weng, Mingzhe; Gong, Wei; Ma, Mingzhe et al. (2014) Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Mol Cancer 13:82
Haller, Sherry L; Peng, Chen; McFadden, Grant et al. (2014) Poxviruses and the evolution of host range and virulence. Infect Genet Evol 21:15-40

Showing the most recent 10 out of 21 publications